Deference Runs Deep
Brooks Kenyon Under 35 U.S.C ยง101, a patent must be either a new and useful process, machine, manufacture, or composition of matter and, thus, must not lay claim to any idea that is abstract. This abstraction can be increasingly difficult to eliminate when drafting software claims because the implementation of code onto a generic computer is somewhat abstract in nature. Areas of software that are, and are not, abstract have been hotly debated and a thorn in the side of court system. Hence, when Justice Thomas opined that the Supreme Court “need not labor to delimit the precise contours of...
Infringe Now–Apologize Later: Is Class Action a Viable Remedy for Songwriters Claiming Copyright Infringement by Spotify?
Ryan Sullivan Spotify’s compensation model pays out royalties to the record labels, which then compensate the artists and performers. However, Spotify cites the record labels as the reason that artists are not getting paid, but that explanation glosses over whether or not Spotify has infringed upon the copyrights by streaming songs that the company does not have the license to. The streaming service is currently facing the threat of two class action lawsuits that allege that their payment model infringes song writers’ copyrights. The two questions, here, are: Has Spotify infringed upon the copyrights of owners of works that the...
The CRISPR Patent Battle: Who Will be “Cut” Out of Patent Rights to One of the Greatest Scientific Discoveries of Our Generation?
Kristin Beale At the center of the United States patent system lies an intricate balance between creating monetary incentives that lead to creation, invention, and discovery, and impeding the flow of the very information that might permit invention. One such invention, that of a novel gene-editing technology called CRISPR-Cas9, has been called one of the “greatest scientific discoveries in the last century.” In simplest terms, the ability to edit genes (the basis of hereditary traits in living organisms made up of DNA) allows scientists to target a specific mutated gene sequence that leads to disease, cut that region out, and,...
The Fair Play, Fair Pay Act of 2015: What’s at Stake and for Whom?
William W. Shields and Jeffrey S. Becker The United States Copyright Act is primed to take center stage during this current legislative session, as several members of Congress introduced comprehensive legislation earlier this year known as the Fair Play, Fair Pay Act of 2015 (FPFPA). This bill seeks to modify the Copyright Act in three key ways. First, it would create a terrestrial public performance right for recording artists and owners of master sound recordings. Second, it would eliminate the Copyright Act’s exemption against federal copyright protection for sound recordings fixed prior to February 15, 1972. Third, it would establish...
Intersection of American Law and Technology: The Innovation Act’s Fight Against Patent Trolls
Mohamed Elfarra The economic and social burdens of frivolous litigation have led “academics, policymakers, and even judges to suggest that patent law[s] may have overleaped its proper bounds, or at least become too likely to frustrate, rather than to fulfill, its constitutional purpose of ‘promot[ing] the progress of science and useful arts’. The primary causes of this problem are the overly litigious entities pejoratively known as patent trolls, who are collectively responsible for the majority of today’s patent infringement cases. Although solutions to this complex problem are evasive, the need for reform is readily apparent. One of the most important...
A Review of the Modern IPR Process
Michael Thomas Once a patent is issued for a drug there is still a chance that the validity of the patent may be challenged. One such way a purported infringer or competitor can challenge a patent’s validity is through an inter partes review (IPR) Process allowed by the United States Patent and Trademark Office (USPTO). Until recently the use of this process by generic drug-makers to invalidate patents has had no success. However, a recent decision by the Patent Trial and Appeal Board (PTAB) gave generic drug-makers their first break when they invalidated the patent for the multiple sclerosis drug...
Obama’s Broadband Plan
Ben Agatston This July, the Council of Economic Advisers (CEA), an administrative office within the Executive Office of the President, published a report that highlighted the “digital divide.” Most notably, the report found that a large number of Americans do not use a computer and “substantial disparities in both Internet use and quality of access.” By exploring Figure 3 of the Council of Economic Adviser’s report, “Mapping the Digital Divide,” it becomes clear that rural areas lag behind more densely populated, urban regions. Read Full Text Here
Telemedicine & the Courts: Teladoc v. Texas Medical Board as a Case Study
Mary Delsener Today, health insurance companies such as Aetna and United Healthcare have partnered with telemedicine companies in order to provide the service for its members. Teladoc, Inc., which markets itself as the first and largest telehealth provider in the United States, is one such company. Of all of business generated by Teladoc’s 11.5 million members, one quarter comes from Texas. Over the course of the past year, however, Teladoc’s ability to continue its services in the state has been on legally tenuous ground due to repeated steps taken by the Texas Medical Board to oust the company from its...
Telemedicine’s Opportunities and Risks; A Balancing Act
Robert Park Obstacles that can complicate successful implementation of telemedicine are the legal ramifications. Legal complications can include fraud and abuse, patient confidentiality, and compliance with state requirements. Violation of patient care can result in heavy fines, and in telemedicine, a recent case involving the Texas Medical Board and a Telemedicine company could heat up within the coming months. Because of these obstacles, healthcare organizations face an arduous journey to getting reimbursed for implementing telemedicine. Read Full Text Here
The Defend Trade Secrets Act: Arrival of the Trade Secret Trolls?
Stephen Anderson A new bill that is currently facing Congress, the Defend Trade Secrets Act, is aimed at creating a federal private cause of action under the Economic Espionage Act of 1996 (EEA). It is a bill that will, if passed, expand the EEA to provide federal jurisdiction for the theft of trade secrets. There is no question as to the degree of importance the protection of trade secrets is to United States businesses and society at large. The question is whether the well-intentioned DTSA will actually do more harm than good. There are a substantial number of legal professionals...